{
    "clinical_study": {
        "@rank": "55353", 
        "arm_group": {
            "arm_group_label": "Sildenafil", 
            "arm_group_type": "Experimental", 
            "description": "motor function to be tested before and after challenge with 100 mg sildenafil after taking normal anti-PD medication, and Again after discontinuation of anti-PD medication for 12 h"
        }, 
        "brief_summary": {
            "textblock": "Sildenafil (Viagra(R))is widely used by men with Parkinsons Disease (PD) and erectile\n      dysfunction. A number of patients have reported that when they take  Sildenafil, their need\n      of anti-PD medication is reduced.\n\n      We hypotheses that sildenafil increases brain blood flow and hence improves the function of\n      specific brain regions, improving motor function.\n\n      Motor function and cerebral blood flow of 8 patients will be tested before and after\n      Sildenafil intake and before and after anti-PD medication."
        }, 
        "brief_title": "Motor Response to Sildenafil in PD", 
        "completion_date": {
            "#text": "March 2004", 
            "@type": "Actual"
        }, 
        "condition": [
            "Parkinsons Disease", 
            "Erectile Dysfunction"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Parkinson Disease", 
                "Erectile Dysfunction"
            ]
        }, 
        "detailed_description": {
            "textblock": "Erectile dysfunction can be experienced by up tp 40% of men with Parkinsons Disease (PD).\n      Sildenafil (Viagra(R))is widely used by men with PD and erectile dysfunction. A number of\n      patients have reported that when they take Sildenafil, their need of anti-PD medication is\n      reduced.\n\n      We hypotheses that sildenafil increases cerebral blood flow in basal ganglia and hence\n      improves the function, improving motor function.\n\n      Motor function and cerebral blood flow (rCBF) of 8 patients will be tested before and after\n      Sildenafil intake and before and after anti-PD medication.\n\n      rCBF will be measured by the Xe133 inhalation method and a fast-rotating, brain-dedicated,\n      single photon emission computerized tomograph (SPECT, Tomomatic, 232, Medimatic, Inc.,\n      Denmark). Two scans will be perfomed, when patients are i)in normal medicated state and ii)\n      in normal medicated state 1 hour after intake of 100 mg sildenafil.\n\n      Motor function will be measured i 4 conditions: i)in normal medicated state and ii) in\n      normal medicated state 1 hour after intake of 100 mg sildenafil, iii) after 12 hours of\n      discontiation of anti-PD mediciation and iiii) after 14 hours of discontiation of anti-PD\n      mediciation and 1 hour after intake of 100 mg sildenafil."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men\n\n          -  Parkinsons disease\n\n          -  Erectile dysfunction\n\n          -  previous tried sildenafil with beneficial effects on motor function\n\n        Exclusion Criteria:\n\n          -  psychosis\n\n          -  Heart disease"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01941732", 
            "org_study_id": "VIA-Pilot1"
        }, 
        "intervention": {
            "arm_group_label": "Sildenafil", 
            "intervention_name": "Sildenafil", 
            "intervention_type": "Drug", 
            "other_name": "Sildenafil (Viagra (R)) 100 mg"
        }, 
        "intervention_browse": {
            "mesh_term": "Sildenafil"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Copenhagen", 
                    "country": "Denmark", 
                    "zip": "DK2400NV"
                }, 
                "name": "Dept of Neurology, Bispebjerg Hospital"
            }
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "1", 
        "official_title": "Motor Response to Acute Challenge to Sildenafil in Parkinsons Disease", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Denmark: Danish Health and Medicines Authority", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2004", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Motor function assessed by Unified Parkinsons disease Rating Scale, section 3 before and after challenge with Sildenafil and before and after discontinuation of anti-PD medication for 12 hours.", 
            "measure": "Motor function", 
            "safety_issue": "No", 
            "time_frame": "1 hour"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01941732"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Bispebjerg Hospital", 
            "investigator_full_name": "Kristian Winge", 
            "investigator_title": "Consultant, ph.d.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "change in rCBF in basal ganglia from before to 1 hour after intake of 100 mg of sildenafil", 
            "measure": "Cerebral Blood Flow (rCBF)", 
            "safety_issue": "No", 
            "time_frame": "1 hour"
        }, 
        "source": "Bispebjerg Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bispebjerg Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2003", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}